Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revolution Medicines reports positive clinical progress and financial stability

Revolution Medicines made significant strides in clinical development and financial stability, despite anticipating increased expenses in 2023
Confidence in the efficacy and tolerability of RMC-6236 and RMC-6291, with a focus on optimizing dosing strategies for future development
Challenges include financial projections for 2023, patient evaluation discrepancies, and the need for more data on dose levels and response rates
Opportunities lie in exploring intermittent dosing, discussing specific response rates, and further data collection for dose optimization

Revolution Medicines reports promising antitumor activity and strengthens financial position

Revolution Medicines showcased progress in their innovative inhibitor programs, bolstered by a successful equity offering. While facing competition and addressing analyst concerns, the company is poised to deliver significant clinical updates and expand their data set for future growth.

Revolution Medicines reports Q2 progress, acquires EQRx for growth

Revolution Medicines showcased financial strength, pipeline progress, and strategic acquisitions, positioning the company for future growth.
While facing challenges in managing expenses and advancing drug candidates, opportunities in pivotal trials and partnerships present avenues for success.
Overall, Revolution Medicines remains optimistic about its clinical developments and financial stability, signaling a promising trajectory in the biopharmaceutical sector.

Revolution Medicines reports strong Q3 results and strategic investment plans

Revolution Medicines showcased promising drug results, bolstered its financial position through an acquisition, and emphasized strategic spending for value creation. Analyst inquiries highlighted the importance of clear communication and effective financial planning for future success.

Revolution Medicines reports robust 2023 performance and strategic growth

Revolution Medicines showcased strong financial performance and progress in 2023.
The company faces challenges in revenue and net loss but sees opportunities in global partnerships and drug combinations.
Strategic priorities for 2024 focus on advancing RAS inhibitors and expanding reach.
Overall, Revolution Medicines is positioned for growth despite facing financial and developmental challenges.

Revolution Medicines advances pivotal cancer trials amidst financial projections

Revolution Medicines is well-capitalized and focused on advancing key therapies.
Facing financial challenges but exploring partnerships and business growth.
Opportunities lie in expanding RMC-6236's efficacy and exploring new indications.

Revolution Medicines excels in Q2 with RAS(ON) inhibitor progress

Revolution Medicines' Q2 performance reflects strong advancements in oncology treatments, supported by a solid financial position and strategic leadership decisions.
While facing challenges in trial execution and financial management, the company's focus on innovation and growth presents significant opportunities for expansion.
Overall, Revolution Medicines is well-positioned to capitalize on the potential of its RAS(ON) inhibitor pipeline and drive future success in the biopharmaceutical industry.

Revolution Medicines reports Q3 loss but shows promise in cancer treatments

Revolution Medicines showcased progress in cancer treatments despite a net loss in Q3 2024. Strong cash reserves, promising data, and strategic collaborations position the company for future growth. Clear communication on financial strategies and upcoming milestones will be crucial for investor confidence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be $230.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on July 22, 2022, subject to customary closing conditions.

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

Board composition evolves as company's development pipeline matures Board composition evolves as company's development pipeline matures

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRAS G12 mutations

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?

REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a live fireside chat at the event.

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants David Errington - Senior Vice President of Investor Relations & Corporate Affairs Mark Goldsmith - Chairman & Chief Executive Officer Jack Anders - Senior Vice President of Finance Conference Call Participants Marc Frahm - Cowen & Company Michael Smith - Guggenheim Christopher Zap - Goldman Sachs Jonathan Chang - SVB Leerink Operator Good day. My name is Katherine, and I'll be your conference facilitator today.

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q1 2022 Results - Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 4.88% and 24.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates

Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

Asana

Ford Motor Company

GameStop

Eastman Kodak

Oric Pharmaceuticals

SoFi Technologies

Here are seven stocks that have recently seen large amounts of insider purchases: Asana (NYSE:ASAN) Ford (NYSE:F) GameStop (NYSE:GME) Eastman Kodak (NYSE:KODK) Oric Pharmaceuticals (NASDAQ:ORIC) Revolution Medicines (NASDAQ:RVMD) Sofi Technologies (NASDAQ:SOFI) The post 7 Stocks That Insiders Are Buying Now. Should You?

7 Stocks That Insiders Are Buying Now. Should You?

JELD-WEN Hld

Qualtrics International

Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain.

Insiders Buy More Than $19M Of 3 Stocks

Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as Presentations in “Chemistry to the Clinic” and “Challenging Targets” Sessions and Pediatric Cancer Working Group Town Hall Meeting Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as Presentations in “Chemistry to the Clinic” and “Challenging Targets” Sessions and Pediatric Cancer Working Group Town Hall Meeting

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q4 2021 Results - Earnings Call Transcript

RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022

REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Guggenheim Healthcare Talks 2022 Oncology Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

RAS(ON) Inhibitor Pipeline Expands with Advancement of Two New Drug Candidates; Development-Stage Portfolio Covers RAS Drivers of Majority of RAS-Addicted Cancers

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the 4th Annual Evercore ISI HealthCONx Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q3 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming Stifel 2021 Virtual Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference

Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Revolution Medicines, Inc. (RVMD) Q3 Earnings Expected to Decline

Conference Call and Webcast Scheduled for Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time

Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021

Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session

Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs

Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23rd Annual Global Investment Conference.

News for Revolution Medicines Stock (RVMD)